A phase II study of the combination chemotherapy of bevacizumab and gemcitabine in women with platinum-resistant recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancer

INTRODUCTION: Bevacizumab and gemcitabine are key drugs for treating recurrent epithelial ovarian cancer. However, information about the combination of bevacizumab and gemcitabine is insufficient. We conducted a phase II study to assess the feasibility, clinical activity, and toxicity of this combin...

Descripción completa

Detalles Bibliográficos
Autores principales: Nagao, Shoji, Kogiku, Ai, Suzuki, Kazuhiro, Shibutani, Takashi, Yamamoto, Kasumi, Jimi, Tomoatsu, Kitai, Miho, Shiozaki, Takaya, Matsuoka, Kazuko, Yamaguchi, Satoshi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7006142/
https://www.ncbi.nlm.nih.gov/pubmed/32028974
http://dx.doi.org/10.1186/s13048-020-0617-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7006142/
https://www.ncbi.nlm.nih.gov/pubmed/32028974
http://dx.doi.org/10.1186/s13048-020-0617-y

Ejemplares similares